



Age/Gender : 33 Y 3 M 10 D/M UHID/MR No : CHSR.0000153412 Visit ID : CHSROPV288331

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275904

Collected : 25/Nov/2023 08:20AM Received : 25/Nov/2023 11:32AM Reported : 25/Nov/2023 12:45PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - F	ULL BODY ANNUAL	L PLUS MALE -	2D ECHO - PAN INDIA	- FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

HAEMOGLOBIN	16.1	g/dL	13-17	Spectrophotometer
PCV	47.90	%	40-50	Electronic pulse & Calculation
RBC COUNT	5.43	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	88.2	fL	83-101	Calculated
MCH	29.6	pg	27-32	Calculated
MCHC	33.6	g/dL	31.5-34.5	Calculated
R.D.W	13.8	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	6,880	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (DLC)			
NEUTROPHILS	48.4	% -	40-80	Electrical Impedance
LYMPHOCYTES	39.9	%	20-40	Electrical Impedance
EOSINOPHILS	2.5	%	1-6	Electrical Impedance
MONOCYTES	8.9	%	2-10	Electrical Impedance
BASOPHILS	0.3	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	3329.92	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	2745.12	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	172	Cells/cu.mm	20-500	Calculated
MONOCYTES	612.32	Cells/cu.mm	200-1000	Calculated
BASOPHILS	20.64	Cells/cu.mm	0-100	Calculated
PLATELET COUNT	233000	cells/cu.mm	150000-410000	Electrical impedence
ERYTHROCYTE SEDIMENTATION RATE (ESR)	5	mm at the end of 1 hour	0-15	Modified Westegren method

RBC NORMOCYTIC NORMOCHROMIC WBC WITHIN NORMAL LIMITS

PLATELETS ARE ADEQUATE ON SMEAR

NO HEMOPARASITES SEEN

IMPRESSION: NORMOCYTIC NORMOCHROMIC BLOOD PICTURE

Page 1 of 13

SIN No:BED230289167

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)

Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telang www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744 na - 500 016 | APOLLO CLINICS NETWORK

Aduress: 323/100/123, Doddathangur Village, Neeladri Main Road, Neeladri Nagar, Electronic city, Bengaluru, Karnataka- 560034







: Mr.GURUGUBELLI VENKATA PRASAD

Age/Gender UHID/MR No : 33 Y 3 M 10 D/M : CHSR.0000153412

Visit ID

: CHSROPV288331

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275904 Collected

: 25/Nov/2023 08:20AM

Received

: 25/Nov/2023 11:32AM : 25/Nov/2023 02:20PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method

BI OOD GRO	NID ARO AND R	H EACTOR I	NHOLE BLOOD EDTA	

BLOOD GROUP ABO AND REFACTOR, WHOLE BLOOD EDTA				
BLOOD GROUP TYPE	A	Microplate		
		Hemagglutination		
Rh TYPE	Positive	Microplate		
		Hemagglutination		

Page 2 of 13

SIN No:BED230289167

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Address: 323/100/123, Doddathangur Village, Neeladri Main Road, Neeladri Nagar, Electronic city, Bengaluru, Karnataka-560034







: Mr.GURUGUBELLI VENKATA PRASAD

Age/Gender UHID/MR No : 33 Y 3 M 10 D/M : CHSR.0000153412

Visit ID

: CHSROPV288331

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275904 Collected

: 25/Nov/2023 08:20AM

Received

: 25/Nov/2023 11:45AM : 25/Nov/2023 12:11PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method	

GLUCOSE, FASTING, NAF PLASMA	89	mg/dL	70-100	HEXOKINASE
------------------------------	----	-------	--------	------------

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Page 3 of 13

SIN No:PLF02059160

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Address: 323/100/123, Doddathangur Village, Neeladri Main Road, Neeladri Nagar, Electronic city, Bengaluru, Karnataka-560034







Age/Gender : 33 Y 3 M 10 D/M
UHID/MR No : CHSR.0000153412
Visit ID : CHSROPV288331

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275904 Collected : 25/Nov/2023 08:20AM Received : 25/Nov/2023 11:39AM

Reported : 25/Nov/2023 12:19PM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - F	ULL BODY ANNUAL	L PLUS MALE -	2D ECHO - PAN INDIA -	- FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

GLUCOSE, POST PRANDIAL (PP), 2	79	mg/dL	70-140	HEXOKINASE
HOURS, SODIUM FLUORIDE PLASMA (2				
HR)				

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

HBA1C, GLYCATED HEMOGLOBIN , WHOLE BLOOD EDTA	5.4	%	HPLC
ESTIMATED AVERAGE GLUCOSE (eAG),	108	mg/dL	Calculated
WHOLE BLOOD EDTA			

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- $2.\ Trends\ in\ HbA1C\ values\ is\ a\ better\ indicator\ of\ Glycemic\ control\ than\ a\ single\ test.$
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.

Page 4 of 13

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

323/100/123, Doddathangur Village, Neeladri Main Road, Neeladri Nagar, Electronic city, Bengaluru, Karnataka-560034







: Mr.GURUGUBELLI VENKATA PRASAD

Age/Gender

: 33 Y 3 M 10 D/M

UHID/MR No Visit ID : CHSR.0000153412 : CHSROPV288331

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275904 Collected

: 25/Nov/2023 08:20AM

Received

: 25/Nov/2023 11:39AM : 25/Nov/2023 12:19PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name Result Unit Bio. Ref. Range Method

5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control A: HbF>25%

B: Homozygous Hemoglobinopathy.

(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 5 of 13



SIN No:PLP1390110,EDT230105888
NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







Age/Gender : 33 Y 3 M 10 D/M UHID/MR No : CHSR.0000153412 Visit ID : CHSROPV288331

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275904

Collected : 25/Nov/2023 08:20AM Received : 25/Nov/2023 12:22PM

: 25/Nov/2023 01:54PM Reported

: Final Report : ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF BIOCHEMISTRY

	DEI /III TIMEITI OI	Bioditelinorik	•	
ARCOFEMI - MEDIWHEEL	- FULL BODY ANNUA	I PLUS MALF -	2D FCHO - PAN INDIA -	FY2324
7(1(OO) EIIII IIIEBIIVIIEEE	. TOLL BODT ANNOT		25 20110 17111 111517	1 1202
Test Name	Result	Unit	Bio. Ref. Range	Method
10011140	Hoodii	J	Diet Keit Kange	

Status

LIPID PROFILE , SERUM				
TOTAL CHOLESTEROL	196	mg/dL	<200	CHO-POD
TRIGLYCERIDES	157	mg/dL	<150	GPO-POD
HDL CHOLESTEROL	39	mg/dL	40-60	Enzymatic Immunoinhibition
NON-HDL CHOLESTEROL	158	mg/dL	<130	Calculated
LDL CHOLESTEROL	126.1	mg/dL	<100	Calculated
VLDL CHOLESTEROL	31.4	mg/dL	<30	Calculated
CHOL / HDL RATIO	5.04		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
.DL.	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60	3		
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- 4. Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- 5. As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 6 of 13

SIN No:SE04549684

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

323/100/123, Doddathangur Village, Neeladri Main Road Neeladri Nagar, Electronic city, Bengaluru, Karnataka- 560034







: Mr.GURUGUBELLI VENKATA PRASAD

Age/Gender

: 33 Y 3 M 10 D/M

UHID/MR No Visit ID : CHSR.0000153412

Ref Doctor

: CHSROPV288331

Emp/Auth/TPA ID

: Dr.SELF : 275904 Collected

: 25/Nov/2023 08:20AM

Received

: 25/Nov/2023 12:22PM

Reported

: 25/Nov/2023 01:54PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

IVER FUNCTION TEST (LFT) , SERUM				
BILIRUBIN, TOTAL	0.72	mg/dL	0.3-1.2	DPD
BILIRUBIN CONJUGATED (DIRECT)	0.12	mg/dL	<0.2	DPD
BILIRUBIN (INDIRECT)	0.60	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	21	U/L	<50	IFCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	23.0	U/L	<50	IFCC
ALKALINE PHOSPHATASE	47.00	U/L	30-120	IFCC
PROTEIN, TOTAL	7.50	g/dL	6.6-8.3	Biuret
ALBUMIN	4.63	g/dL	3.5-5.2	BROMO CRESOL GREEN
GLOBULIN	2.87	g/dL	2.0-3.5	Calculated
A/G RATIO	1.61		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.
- Disproportionate increase in AST, ALT compared with ALP.
- Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- · Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.

3. Synthetic function impairment:

- Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

Page 7 of 13







: Mr.GURUGUBELLI VENKATA PRASAD

Age/Gender

: 33 Y 3 M 10 D/M

UHID/MR No Visit ID

: CHSR.0000153412

Ref Doctor

: CHSROPV288331

: Dr.SELF Emp/Auth/TPA ID : 275904

Collected

: 25/Nov/2023 08:20AM

Received Reported

: 25/Nov/2023 12:22PM : 25/Nov/2023 01:54PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name Result Unit Bio. Ref. Range Method

Page 8 of 13



SIN No:SE04549684

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Aduress: 323/100/123, Doddathangur Village, Neeladri Main Road, Neeladri Nagar, Electronic city, Bengaluru, Karnataka- 560034







: Mr.GURUGUBELLI VENKATA PRASAD

Age/Gender UHID/MR No : 33 Y 3 M 10 D/M

Visit ID

: CHSR.0000153412 : CHSROPV288331

Ref Doctor Emp/Auth/TPA ID

CHLORIDE

: Dr.SELF

: 275904

Collected

: 25/Nov/2023 08:20AM

101-109

Received

: 25/Nov/2023 12:22PM : 25/Nov/2023 01:54PM

Reported Status

: Final Report

Sponsor Name

mmol/L

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324						
Test Name	Result	Unit	Bio. Ref. Range	Method		

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT), SERUM				
CREATININE	0.71	mg/dL	0.72 – 1.18	JAFFE METHOD
UREA	22.90	mg/dL	17-43	GLDH, Kinetic Assay
BLOOD UREA NITROGEN	10.7	mg/dL	8.0 - 23.0	Calculated
URIC ACID	6.10	mg/dL	3.5-7.2	Uricase PAP
CALCIUM	9.60	mg/dL	8.8-10.6	Arsenazo III
PHOSPHORUS, INORGANIC	3.66	mg/dL	2.5-4.5	Phosphomolybdate Complex
SODIUM	141	mmol/L	136–146	ISE (Indirect)
POTASSIUM	4.8	mmol/L	3.5–5.1	ISE (Indirect)

104

Page 9 of 13



ISE (Indirect)

SIN No:SE04549684

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Address: 323/100/123, Doddathangur Village, Neeladri Main Road, Neeladri Nagar, Electronic city, Bengaluru, Karnataka- 560034







: Mr.GURUGUBELLI VENKATA PRASAD

Age/Gender UHID/MR No : 33 Y 3 M 10 D/M : CHSR.0000153412

Visit ID

: CHSROPV288331

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275904 Collected

: 25/Nov/2023 08:20AM

Received Reported : 25/Nov/2023 12:22PM : 25/Nov/2023 01:51PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
103t Hullio	Result	Onit	Bio. Rei. Range	wethou

GAMMA GLUTAMYL TRANSPEPTIDASE	32.00	U/L	<55	IFCC	
(GGT) , SERUM					

Page 10 of 13

SIN No:SE04549684

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)

Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telangana - 500 016 | www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744

APOLLO CLINICS NETWORK

Address: 323/100/123, Doddathangur Village, Neeladri Main Road, Neeladri Nagar, Electronic city, Bengaluru, Karnataka-560034







: Mr.GURUGUBELLI VENKATA PRASAD

Age/Gender

: 33 Y 3 M 10 D/M

UHID/MR No Visit ID : CHSR.0000153412 : CHSROPV288331

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 275904

Collected

: 25/Nov/2023 08:20AM

Received

: 25/Nov/2023 12:22PM

Reported

: 25/Nov/2023 02:08PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
-----------	--------	------	-----------------	--------

THYROID PROFILE TOTAL (T3, T4, TSH), SERUM

TRI-IODOTHYRONINE (T3, TOTAL)	1.15	ng/mL	0.7-2.04	CLIA
THYROXINE (T4, TOTAL)	10.15	μg/dL	5.48-14.28	CLIA
THYROID STIMULATING HORMONE (TSH)	4.641	μIU/mL	0.34-5.60	CLIA

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 – 3.0

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- 4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 11 of 13

SIN No:SPL23167296

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE





: Mr.GURUGUBELLI VENKATA PRASAD

Age/Gender

: 33 Y 3 M 10 D/M

UHID/MR No Visit ID

: CHSR.0000153412

Ref Doctor

: CHSROPV288331

: Dr.SELF Emp/Auth/TPA ID : 275904

Collected

: 25/Nov/2023 08:20AM

Received

: 25/Nov/2023 01:23PM

Reported

: 25/Nov/2023 03:16PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method

PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
pH	6.0		5-7.5	DOUBLE INDICATOR
SP. GRAVITY	1.005		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GLUCOSE OXIDASE
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING REACTION
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	SODIUM NITRO PRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	MODIFED EHRLICH REACTION
BLOOD	NEGATIVE		NEGATIVE	Peroxidase
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	LEUCOCYTE ESTERASE
CENTRIFUGED SEDIMENT WET MO	OUNT AND MICROSCOPY			
PUS CELLS	2-3	/hpf	0-5	Microscopy
EPITHELIAL CELLS	1-2	/hpf	<10	MICROSCOPY
RBC	NIL	/hpf	0-2	MICROSCOPY
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Page 12 of 13

SIN No:UR2226465

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Aduress: 323/100/123, Doddathangur Village, Neeladri Main Road, Neeladri Nagar, Electronic city, Bengaluru, Karnataka- 560034







: Mr.GURUGUBELLI VENKATA PRASAD

Age/Gender UHID/MR No : 33 Y 3 M 10 D/M : CHSR.0000153412

Visit ID

: CHSROPV288331

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : 275904

Collected

: 25/Nov/2023 08:20AM

Received

: 25/Nov/2023 01:23PM : 25/Nov/2023 03:12PM

Reported Status

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name Result Unit Bio. Ref. Range Method

URINE GLUCOSE(POST PRANDIAL)

NEGATIVE

NEGATIVE

URINE GLUCOSE(FASTING)

NEGATIVE

NEGATIVE

Dipstick

Dipstick

*** End Of Report ***

Result/s to Follow: PERIPHERAL SMEAR

DR.SHIVARAJA SHETTY M.B.B.S,M.D(Biochemistry) CONSULTANT BIOCHEMIST

Dr. Shobha Emmanuel M.B.B.S, M.D(Pathology) Consultant Pathologist

inki Anupam M.B.B.S,M.D(Pathology) Consultant Pathologist

Page 13 of 13

SIN No:UPP015823,UF009828 NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE



Name: Mr. GURUGUBELLI VENKATA PRASAD

Age: 33 Y

Sex: M

UHID:CHSR.0000153412

OP Number: CHSROPV288331

Bill No: CHSR-OCR-63974


Address: hsr

Plan

: ARCOFEMI MEDIWHEEL MALE AHC CREDIT PAN

INDIA OP AGREEMENT

Date : 25.11.2023 08:04 Sno Serive Type/ServiceName Department ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 → URINE GLUCOSE(FASTING) 2 GAMMA GLUTAMYL TRANFERASE (GGT) 3 HbAIc, GLYCATED HEMOGLOBIN 4 2 D ECHO 5 LIVER FUNCTION TEST (LFT) X-RAY CHEST PA 7 GLUCOSE, FASTING 8 HEMOGRAM + PERIPHERAL SMEAR 9 ENT CONSULTATION _ 5'30 10 FITNESS BY GENERAL PHYSICIAN 11 DIET CONSULTATION 12 COMPLETE URINE EXAMINATION 13 URINE GLUCOSE(POST PRANDIAL) 14 PERIPHERAL SMEAR 15 ECG 16 BLOOD GROUP ABO AND RH FACTOR LIPID PROFILE 18 BODY MASS INDEX (BMI) LOOPTHAL BY GENERAL PHYSICIAN ____ 20 RENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT) 2 ULTRASOUND - WHOLE ABDOMEN - 14 22 THYROID PROFILE (TOTAL T3, TOTAL T4, TSH) 23 DENTAL CONSULTATION 24 LUCOSE, POST PRANDIAL (PP), 2 HOURS (POST MEAL)







Mr. Venkerta. Prasciol. Maall-133y 28/11/23

Height:	Weight:	вмі :	Waist Circum :
Temp :	Pulse :	Resp:	B.P:

General Examination / Allergies History

Clinical Diagnosis & Management Plan

016

No abnormality dutuded



Follow up date:

Doctor Signature





: 25-11-2023

MR NO

: CHSR.0000153412

Department

GENERAL

Doctor

Name

: Mr. GURUGUBELLI VENKATA PR

Registration No

Age/ Gender

33 Y / Male

Qualification

Consultation Timing: 08:02

Height: \G8	Weight: 75.9kg	BMI:	Waist Circum :
Temp :	Pulse:	Resp:	B.P: 120/75

General Examination / Allergies History

Clinical Diagnosis & Management Plan

optual
66 voitu 66
016 voitevout relt
016 voitevout 17
17
17

Dry Eyes! Lubred Eye Drop. D 1-1-1 Dwks

Follow up date:

Doctor Signature





Patient Name : Mr. GURUGUBELLI VENKATA PRASAD Age/Gender : 33 Y/M

Sample Collected on : Reported on : 26-11-2023 10:21

Ref Doctor : SELF **Emp/Auth/TPA ID** : 275904

DEPARTMENT OF RADIOLOGY

X-RAY CHEST PA

Bilateral lung fields appear normal.

Cardiac size and shape are normal.

No mediastinal pathology is seen.

Both hila are normal in size and density.

Both CP angles are normal.

Both domes of diaphragm are normal.

IMPRESSION: NORMAL STUDY.

(The findings should always be considered in correlation with the clinical and other investigation finding where applicable.) It is only a professional opinion, Not valid for medico legal purpose.

Dr. VIGNESH K

MBBS, MD Radio-Diagnosis

Radiology



Patient Name : Mr. GURUGUBELLI VENKATA PRASAD Age/Gender : 33 Y/M

UHID/MR No.

: CHSR.0000153412

Sample Collected on

LRN#

: RAD2159345

Ref Doctor : SELF **Emp/Auth/TPA ID** : 275904

OP Visit No : CHSROPV288331

Reported on : 25-11-2023 08:52 **Specimen** :

DEPARTMENT OF RADIOLOGY

ULTRASOUND - WHOLE ABDOMEN

LIVER: Normal in size 14 cm and echotexture. No intra hepatic biliary / venous radicular dilation. No focal lesion seen. CBD and Main Portal vein appear normal.

GALL BLADDER: Well distended. Lumen is clear. Wall Thickness is normal.

SPLEEN: Normal in size and echotexture. No focal lesion was seen. No evidence of splenic hilar varices / collaterals.

PANCREAS: Only head and body visualized, appear normal.

KIDNEYS: Both kidneys are normal in size, shape and outlines Cortico medullary delineation is normal. No hydronephrosis / No calculi.

URINARY BLADDER: Well distended. Normal in internal contents. Wall thickness is normal

PROSTATE: Normal in size and echotexture. No focal lesion is seen.

Prostate appears normal, volume is 15 cc.

No free fluid is seen in the peritoneum.

IMPRESSION:

· No Significant Abnormality Seen.

(The sonography findings should always be considered in correlation with the clinical and other investigation finding where applicable.) It is only a professional opinion, Not valid for medico legal purpose.

Dr. VIGNESH K
MBBS, MD Radio-Diagnosis
Radiology

Name: Mr. GURUGUBELLI VENKATA PRASAD

Age/Gender: 33 Y/M Address: hsr

Location: BANGALORE, KARNATAKA

Doctor:

Department: GENERAL

Rate Plan: HSR LAYOUT_06042023

Sponsor: ARCOFEMI HEALTHCARE LIMITED

Consulting Doctor: Dr. KARISHMA PATEL

Doctor's Signature

MR No: CHSR.0000153412 Visit ID: CHSROPV288331 Visit Date: 25-11-2023 08:02

Discharge Date:

Referred By: SELF

Mr. GURUGUBELLI VENKATA PRASAD

Age/Gender: 33 Y/M hsr Address:

Location: BANGALORE, KARNATAKA

Doctor:

Department: GENERAL
Rate Plan: HSR LAYO
Sponsor: ARCOFEMI HSR LAYOUT_06042023

ARCOFEMI HEALTHCARE LIMITED Sponsor:

Consulting Doctor: Dr. ARPITA SUBHASH

HT-CHIEF COMPLAINTS AND PRESENT KNOWN ILLNESS

SYSTEMIC REVIEW

HT-HISTORY

PHYSICAL EXAMINATION

SYSTEMIC EXAMINATION

IMPRESSION

RECOMMENDATION

Doctor's Signature

MR No: CHSR.0000153412 CHSROPV288331 Visit ID: Visit Date: 25-11-2023 08:02

Discharge Date:

Referred By: SELF Mr. GURUGUBELLI VENKATA PRASAD

Age/Gender: 33 Y/M hsr Address:

Location: BANGALORE, KARNATAKA

Doctor:

Department: GENERAL
Rate Plan: HSR LAYO
Sponsor: ARCOFFMI HSR LAYOUT_06042023

ARCOFEMI HEALTHCARE LIMITED Sponsor:

Consulting Doctor: Dr. KAVYA J

HT-CHIEF COMPLAINTS AND PRESENT KNOWN ILLNESS

SYSTEMIC REVIEW

HT-HISTORY

PHYSICAL EXAMINATION

SYSTEMIC EXAMINATION

IMPRESSION

RECOMMENDATION

Doctor's Signature

MR No: CHSR.0000153412 CHSROPV288331 Visit ID: Visit Date: 25-11-2023 08:02

Discharge Date:

Referred By: SELF Name: Mr. GURUGUBELLI VENKATA PRASAD

Age/Gender: 33 Y/M Address: hsr

Location: BANGALORE, KARNATAKA

Doctor:

Department: GENERAL

Rate Plan: HSR LAYOUT_06042023

Sponsor: ARCOFEMI HEALTHCARE LIMITED

Consulting Doctor: Dr. MRIDULA V AMARNATH

Doctor's Signature

MR No: CHSR.0000153412 Visit ID: CHSROPV288331 Visit Date: 25-11-2023 08:02

Discharge Date:

Referred By: SELF

II)afe	Pulse (Beats/min)	_	Resp (Rate/min)	Temp (F)	Height (cms)	(Kgs)	Percentage	Fat Level	Body Age (Years)	BMI	Circum	Hip (cms)	(cms)	Waist & Hip Ratio	User
25-11-2023 17:44			20 Rate/min	98 F		75.9 Kgs	%	%	Years	26.89	cms	cms	cms		AHLL10116

II)afe	Pulse (Beats/min)	_	Resp (Rate/min)	Temp (F)	Height (cms)	(Kgs)	Percentage	Fat Level	Body Age (Years)	BMI	Circum	Hip (cms)	(cms)	Waist & Hip Ratio	User
25-11-2023 17:44			20 Rate/min	98 F		75.9 Kgs	%	%	Years	26.89	cms	cms	cms		AHLL10116

II)afe	Pulse (Beats/min)	_	Resp (Rate/min)	Temp (F)	Height (cms)	(Kgs)	Percentage	Fat Level	Body Age (Years)	BMI	Circum	Hip (cms)	(cms)	Waist & Hip Ratio	User
25-11-2023 17:44			20 Rate/min	98 F		75.9 Kgs	%	%	Years	26.89	cms	cms	cms		AHLL10116

II)afe	Pulse (Beats/min)	_	Resp (Rate/min)	Temp (F)	Height (cms)	(Kgs)	Percentage	Fat Level	Body Age (Years)	BMI	Circum	Hip (cms)	(cms)	Waist & Hip Ratio	User
25-11-2023 17:44			20 Rate/min	98 F		75.9 Kgs	%	%	Years	26.89	cms	cms	cms		AHLL10116

PRASAD

: 33 Y/M

Age

 UHID
 : CHSR.0000153412
 OP Visit No
 : CHSROPV288331

 Conducted By:
 :
 Conducted Date
 : 25-11-2023 18:08

Referred By : SELF

• :2D Echo Cardiography

• Chambers

• Left Ventricle :Normal in size, NO RWMA at Rest

Left Atrium : NormalRight Ventricle : NormalRight Atrium : Normal

• Septa

IVS: Intact

• IAS: Intact

Valves

• Mitral Valve: Normal.

Tricuspid Valve: Normal, Trace TR, No PAHAortic Valve: Tricuspid, Normal mobility

• Pulmonary Valve : Normal

Great Valves

• Aorta : Normal

• Pulmonary Artery: Normal

PRASAD

Age : 33 Y/M

UHID : CHSR.0000153412 OP Visit No : CHSROPV288331

Conducted By: : Conducted Date : 25-11-2023 18:08

Referred By : SELF

Pericardium: Normal

Doppler Echocardiograph

Mitral Valve E 0.83 m/sec A 0.54 m/sec e/a 1.55

Aortic Valve Vmax 1.4 m/sec PG 7.9 mm

Distolic Dysfunction None

M – Mode Measurement

Parameter	Observed Valve	Normal Range	
Aorta	25	26- 36	mm
Left Atrium	27	27-38	mm
IVS- Diastole	11	09-11	mm
Left Ventricle –Diastole	44	42-59	mm
Posterior wall-Diastole	11	09-11	mm
IVS-Systole	15	13-15	mm
Left Ventricle- Systole	26	21-40	mm
Posterior wall- Systole	15	13-15	mm
Ejection Fraction	60%	->50	%

IMPRESSION

• NORMAL SIZED CARDIAC VALVES AND CHAMBERS

PRASAD Age : 33 Y/M

UHID : CHSR.0000153412 OP Visit No : CHSROPV288331

Conducted By: : Conducted Date

Referred By : SELF

• NO RWMA'S AT REST

• NORMAL LV & RV SYSTOLIC FUNCTION LVEF - 60%

• NORMAL LV DIASTOLIC FUNCTION

• NO PERICARDIAL EFFUSION / VEGETATION / CLOT.

Dr RAMNARESH SOUDRI MD, DM (CARDIOLOGY), FSCAI Consultant Interventional Cardiologist

: 25-11-2023 18:08

Age/Gender : 33 Y 3 M 10 D/M UHID/MR No : CHSR.0000153412 Visit ID : CHSROPV288331

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275904

Collected : 25/Nov/2023 08:20AM Received : 25/Nov/2023 11:32AM Reported : 25/Nov/2023 12:45PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF HAEMATOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 **Test Name** Result Unit Bio. Ref. Range Method

HAEMOGLOBIN	16.1	g/dL	13-17	Spectrophotometer
PCV	47.90	%	40-50	Electronic pulse & Calculation
RBC COUNT	5.43	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	88.2	fL	83-101	Calculated
MCH	29.6	pg	27-32	Calculated
MCHC	33.6	g/dL	31.5-34.5	Calculated
R.D.W	13.8	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	6,880	cells/cu.mm	4000-10000	Electrical Impedanc
DIFFERENTIAL LEUCOCYTIC COUNT (E	LC)			
NEUTROPHILS	48.4	%	40-80	Electrical Impedanc
LYMPHOCYTES	39.9	%	20-40	Electrical Impedance
EOSINOPHILS	2.5	%	1-6	Electrical Impedanc
MONOCYTES	8.9	%	2-10	Electrical Impedanc
BASOPHILS	0.3	%	<1-2	Electrical Impedanc
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	3329.92	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	2745.12	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	172	Cells/cu.mm	20-500	Calculated
MONOCYTES	612.32	Cells/cu.mm	200-1000	Calculated
BASOPHILS	20.64	Cells/cu.mm	0-100	Calculated
PLATELET COUNT	233000	cells/cu.mm	150000-410000	Electrical impedenc
ERYTHROCYTE SEDIMENTATION	5	mm at the end	0-15	Modified Westegrer

RBC NORMOCYTIC NORMOCHROMIC WBC WITHIN NORMAL LIMITS PLATELETS ARE ADEQUATE ON SMEAR

NO HEMOPARASITES SEEN

IMPRESSION: NORMOCYTIC NORMOCHROMIC BLOOD PICTURE



Age/Gender : 33 Y 3 M 10 D/M
UHID/MR No : CHSR.0000153412
Visit ID : CHSROPV288331

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275904

 Collected
 : 25/Nov/2023 08:20AM

 Received
 : 25/Nov/2023 11:32AM

 Reported
 : 25/Nov/2023 02:20PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

	DEPARTMENT OF	HAEMATOLOG	Υ							
ARCOFEMI - MEDIWHEEL - I	FULL BODY ANNUA	L PLUS MALE -	2D ECHO - PAN INDIA	- FY2324						
Test Name Result Unit Bio. Ref. Range Method										

BLOOD GROUP ABO AND RH FACTOR,	WHOLE BLOOD EDTA	
BLOOD GROUP TYPE	A	Microplate Hemagglutination
Rh TYPE	Positive	Microplate Hemagglutination



Age/Gender : 33 Y 3 M 10 D/M
UHID/MR No : CHSR.0000153412
Visit ID : CHSROPV288331

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275904 | Collected : 25/Nov/2023 08:20AM | Received : 25/Nov/2023 11:45AM | Reported : 25/Nov/2023 12:11PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - F	ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324							
Test Name	Result	Unit	Bio. Ref. Range	Method				

GLUCOSE, FASTING, NAF PLASMA	89	mg/dL	70-100	HEXOKINASE	
------------------------------	----	-------	--------	------------	--

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- $2. \ Very \ high \ glucose \ levels \ (>\!\!450 \ mg/dL \ in \ adults) \ may \ result \ in \ Diabetic \ Ketoacidosis \ \& \ is \ considered \ critical.$



Age/Gender : 33 Y 3 M 10 D/M
UHID/MR No : CHSR.0000153412
Visit ID : CHSROPV288331

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275904 | Collected : 25/Nov/2023 08:20AM | Received : 25/Nov/2023 11:39AM | Reported : 25/Nov/2023 12:19PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324				
Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, POST PRANDIAL (PP), 2	79	mg/dL	70-140	HEXOKINASE

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

HBA1C, GLYCATED HEMOGLOBIN , WHOLE BLOOD EDTA	5.4	%	HPLC
ESTIMATED AVERAGE GLUCOSE (eAG), WHOLE BLOOD EDTA	108	mg/dL	Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- $2.\ Trends\ in\ HbA1C\ values\ is\ a\ better\ indicator\ of\ Glycemic\ control\ than\ a\ single\ test.$
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.

Page 4 of 13

Age/Gender : 33 Y 3 M 10 D/M
UHID/MR No : CHSR.0000153412
Visit ID : CHSROPV288331

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : 275904

| Collected : 25/Nov/2023 08:20AM | Received : 25/Nov/2023 11:39AM | Reported : 25/Nov/2023 12:19PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - F	ULL BODY ANNUA	L PLUS MALE -	2D ECHO - PAN INDIA	- FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control A: HbF >25%

B: Homozygous Hemoglobinopathy.

(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)



Age/Gender : 33 Y 3 M 10 D/M
UHID/MR No : CHSR.0000153412
Visit ID : CHSROPV288331

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : 275904

Collected : 25/Nov/2023 08:20AM
Received : 25/Nov/2023 12:22PM

Reported : 25/Nov/2023 01:54PM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

DELYNCHMENT OF BIOGRAPHICTRY							
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324							
Test Name	Result	Unit	Bio. Ref. Range	Method			

LIPID PROFILE , SERUM				
TOTAL CHOLESTEROL	196	mg/dL	<200	CHO-POD
TRIGLYCERIDES	157	mg/dL	<150	GPO-POD
HDL CHOLESTEROL	39	mg/dL	40-60	Enzymatic Immunoinhibition
NON-HDL CHOLESTEROL	158	mg/dL	<130	Calculated
LDL CHOLESTEROL	126.1	mg/dL	<100	Calculated
VLDL CHOLESTEROL	31.4	mg/dL	<30	Calculated
CHOL / HDL RATIO	5.04		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
III .IDI .	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
INON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- **4.** Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.



Age/Gender : 33 Y 3 M 10 D/M
UHID/MR No : CHSR.0000153412
Visit ID : CHSROPV288331

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275904

 Collected
 : 25/Nov/2023 08:20AM

 Received
 : 25/Nov/2023 12:22PM

 Reported
 : 25/Nov/2023 01:54PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

LIVER FUNCTION TEST (LFT), SERUM				
BILIRUBIN, TOTAL	0.72	mg/dL	0.3-1.2	DPD
BILIRUBIN CONJUGATED (DIRECT)	0.12	mg/dL	<0.2	DPD
BILIRUBIN (INDIRECT)	0.60	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	21	U/L	<50	IFCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	23.0	U/L	<50	IFCC
ALKALINE PHOSPHATASE	47.00	U/L	30-120	IFCC
PROTEIN, TOTAL	7.50	g/dL	6.6-8.3	Biuret
ALBUMIN	4.63	g/dL	3.5-5.2	BROMO CRESOL GREEN
GLOBULIN	2.87	g/dL	2.0-3.5	Calculated
A/G RATIO	1.61		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.
- Disproportionate increase in AST, ALT compared with ALP.
- Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.

3. Synthetic function impairment:

- \bullet Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

Age/Gender : 33 Y 3 M 10 D/M
UHID/MR No : CHSR.0000153412
Visit ID : CHSROPV288331

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275904 Collected : 25/Nov/2023 08:20AM
Received : 25/Nov/2023 12:22PM
Reported : 25/Nov/2023 01:54PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY	ANNUAL PLUS MALE -	2D ECHO - PAN INDIA - FY2324
----------------------------------	--------------------	------------------------------

Test Name Result Unit Bio. Ref. Range Method



Age/Gender : 33 Y 3 M 10 D/M
UHID/MR No : CHSR.0000153412
Visit ID : CHSROPV288331

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275904 Collected : 25/Nov/2023 08:20AM
Received : 25/Nov/2023 12:22PM
Reported : 25/Nov/2023 01:54PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM					
CREATININE	0.71	mg/dL	0.72 – 1.18	JAFFE METHOD	
UREA	22.90	mg/dL	17-43	GLDH, Kinetic Assay	
BLOOD UREA NITROGEN	10.7	mg/dL	8.0 - 23.0	Calculated	
URIC ACID	6.10	mg/dL	3.5–7.2	Uricase PAP	
CALCIUM	9.60	mg/dL	8.8-10.6	Arsenazo III	
PHOSPHORUS, INORGANIC	3.66	mg/dL	2.5-4.5	Phosphomolybdate Complex	
SODIUM	141	mmol/L	136–146	ISE (Indirect)	
POTASSIUM	4.8	mmol/L	3.5-5.1	ISE (Indirect)	
CHLORIDE	104	mmol/L	101–109	ISE (Indirect)	



Age/Gender : 33 Y 3 M 10 D/M
UHID/MR No : CHSR.0000153412
Visit ID : CHSROPV288331

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275904 Collected : 25/Nov/2023 08:20AM
Received : 25/Nov/2023 12:22PM
Reported : 25/Nov/2023 01:51PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

	DEPARTMENT OF	BIOCHEMISTR	Υ		
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324					
Test Name Result Unit Bio. Ref. Range Method					
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT), SERUM	32.00	U/L	<55	IFCC	

Age/Gender : 33 Y 3 M 10 D/M
UHID/MR No : CHSR.0000153412
Visit ID : CHSROPV288331

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : 275904

Collected : 25/Nov/2023 08:20AM Received : 25/Nov/2023 12:22PM

Reported : 25/Nov/2023 02:08PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

			•		
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

THYROID PROFILE TOTAL (T3, T4, TSH), SERUM					
TRI-IODOTHYRONINE (T3, TOTAL)	1.15	ng/mL	0.7-2.04	CLIA	
THYROXINE (T4, TOTAL)	10.15	μg/dL	5.48-14.28	CLIA	
THYROID STIMULATING HORMONE (TSH)	4.641	μIU/mL	0.34-5.60	CLIA	

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)	
First trimester	0.1 - 2.5	
Second trimester	0.2 - 3.0	
Third trimester	0.3 – 3.0	

- **1.** TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- **3.** Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- 4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma



COMPLETE LIDINE EXAMINATION (CLIE) LIDINE

Age/Gender : 33 Y 3 M 10 D/M
UHID/MR No : CHSR.0000153412
Visit ID : CHSROPV288331

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275904 Collected : 25/Nov/2023 08:20AM
Received : 25/Nov/2023 01:23PM
Reported : 25/Nov/2023 03:16PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

COMPLETE URINE EXAMINATION (C	UE), URINE			
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
рН	6.0		5-7.5	DOUBLE INDICATOR
SP. GRAVITY	1.005		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GLUCOSE OXIDASE
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING REACTION
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	SODIUM NITRO PRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	MODIFED EHRLICH REACTION
BLOOD	NEGATIVE		NEGATIVE	Peroxidase
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	LEUCOCYTE ESTERASE
CENTRIFUGED SEDIMENT WET MO	OUNT AND MICROSCOPY			
PUS CELLS	2-3	/hpf	0-5	Microscopy
EPITHELIAL CELLS	1-2	/hpf	<10	MICROSCOPY
RBC	NIL	/hpf	0-2	MICROSCOPY
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY



Age/Gender : 33 Y 3 M 10 D/M
UHID/MR No : CHSR.0000153412
Visit ID : CHSROPV288331

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275904 | Collected : 25/Nov/2023 08:20AM | Received : 25/Nov/2023 01:23PM | Reported : 25/Nov/2023 03:12PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY						
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324						
Test Name	Result	Unit	Bio. Ref. Range Metho			
IDINE OF HOOSE/DOST DRANDIAL)	NEC ATIVE		NICO ATIVE	Dinatials		
URINE GLUCOSE(POST PRANDIAL)	NEGATIVE		NEGATIVE	Dipstick		
URINE GLUCOSE(FASTING)	NEGATIVE		NEGATIVE	Dinstick		

*** End Of Report ***

Result/s to Follow: PERIPHERAL SMEAR

DR.SHIVARAJA SHETTY
M.B.B.S,M.D(Biochemistry)
CONSULTANT BIOCHEMIST

Dr.Shobha Emmanuel M.B.B.S,M.D(Pathology) Consultant Pathologist Dr. Chinki Anupam M.B.B.S,M.D(Pathology) Consultant Pathologist

